Search
Powered By HealthLine
Health Tools
 Children's Allergies Q&A
 Childhood Asthma Guide
 Childhood Asthma Prognosis
 Identifying Depression in Children
 Treating Childhood Depression
Featured Conditions
 Cold & Flu
 Allergy
 Asthma
 Depression
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Grim News About Childhood Heart Disease

Ivanhoe Broadcast News


Related Encyclopedia
 border=
Acne
Alagille Syndrome
Appendicitis
Asthma in Children
More...

Related Animations
 border=
Dental Cavities
More...

Related Healthscout Videos
 border=
Coming Around: Coma Breakthroughs
Baby Steps: Fertility Findings
Saving Infants from Killer Bacteria: NEC
The New Tooth Fairy: Banking Dental Stem Cells
More...

Related Drug Information
 border=
Adderal XR
Concerta
Strattera
More...

Related News Articles
 border=
Prenatal Antipsychotic Drugs Linked to Motor Delays: Study
Coffee Drinking in Pregnancy Won't Lead to Sleepless Baby: Study
Young Women Who Drink and Drive at Higher Risk of Fatal Accident
1 in 5 Pharmacies Hinders Teens' Access to 'Morning-After' Pill: Study
More...

(Ivanhoe Newswire) -- Scientists have discovered grim news about a recently recognized and rare type of genetic heart disorder -- it progresses rapidly and often results in early death, according to a new study.

Mutations in the lysosome-associated membrane protein gene (called LAMP2) produce cardiomyopathy, or a disorder of the heart muscle, in young patients that is similar to severe hypertrophic cardiomyopathy, a condition in which the heart muscle becomes thick, making it harder for blood to leave the heart and forcing the heart to work harder to pump blood.

Text Continues Below



This disorder, which is also called Danon disease, usually affects young boys. Researchers said their study found that clinical deterioration is often rapid, with the time interval from clinical stability with little or no symptoms to end-stage heart failure as brief as six months.

In their study, diagnosis was the result of a heart murmur, family screening and findings on routine electrocardiogram (ECG) or by symptoms such as chest pain or fainting. The seven children involved in the study were between 7 and 17 years old at the time of diagnosis, and during the subsequent average time of 8.6 years after diagnosis, each of the patients experienced serious adverse clinical consequences by 14 to 24 years of age. Four of the patients died and one underwent a heart transplant.

The researchers called Danon disease "one of the most lethal cardiomyopathies in young and usually male patients."

"The early experience with the distinctive natural history and prognosis of patients with LAMP2 mutations establishes the importance of molecular diagnosis and underscores the utility of genetic testing," the authors said.

SOURCE: Journal of the American Medical Association, 2009;301:1253-1259


If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Melissa Medalie at mmedalie@ivanhoe.com

 

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 3/27/2009

Related Links
 border=
From Healthscout's partner site on adhd, ADHDCentral.com
Find tips for parenting children with ADHD
Learn how to cope with Adult ADHD
What treatment options are available for ADHD?





HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire